Bayforest Capital’s GSK GSK Stock Holding History

Bayforest Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-8,204	Closed	-$402K	–	980
2025 Q4	$402K	Sell	8,204 -767	-9%	-$35.8K	0.3%	65
2025 Q3	$387K	Buy	8,971 +2,647	+42%	+$103K	0.18%	215
2025 Q2	$243K	Buy	+6,324	New	+$242K	0.11%	341
2025 Q1	–	Sell	-2,356	Closed	-$79.7K	–	795
2024 Q4	$79.7K	Buy	+2,356	New	+$84.8K	0.1%	365

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Bayforest Capital's GSK Position: Q1 2026 in Review

Bayforest Capital sold out of GSK (GSK) in Q1 2026, closing a stake of 8,204 shares — an estimated $402K sold.

Bayforest Capital first reported a position in GSK in Q4 2024 and held it in 4 quarters. The position peaked at $402K in Q4 2025. 1,035 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Bayforest Capital reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Bayforest Capital sold 8,204 GSK shares in Q1 2026, an estimated $402K.
Bayforest Capital first reported a position in GSK in Q4 2024 and held it in 4 quarters.
Bayforest Capital's GSK position peaked at $402K in Q4 2025.
1,035 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.